Even though a variety of experimental findings have demonstrated the effective contribution of TGFβ2 in patients with glaucoma, the relationship between glaucoma and TGFβ1 has needed further investigation, which has led to the use of OMT, a TGFβ1 antagonist extracted from the roots of Sophora flavescens Ait, belonging to the family Fabaceae and a known savior for patients with fibrotic diseases (12–14). Here, TGFB2 is linked to glaucoma.